###### Strengths and limitations of this study

-   UK Biobank is the largest prospective cohort with extensive measures on ophthalmic diseases and conditions.

-   Repeated physical measures every few years and linkage to National Health Service records will provide valuable information on health outcomes.

-   A large number of incident cases of eye diseases in 5 years will allow the detection and quantification of small effect sizes.

-   A low response rate (5.5%).

Introduction {#s1}
============

Ageing populations worldwide face an increasing burden of chronic and neurodegenerative diseases,[@R1] resulting in substantial health and economic burdens.[@R2] Chronic age-related eye diseases, such as age-related macular degeneration (AMD), diabetic retinopathy (DR) and glaucoma, are leading causes of visual impairment in Western populations. Increased intraocular pressure (IOP) is one of the most significant risk factors for the development[@R4] and progression[@R5] of glaucoma. A recent study from the UK Biobank demonstrated that factors including diabetes, height, smoking and black ethnicity have different associations with Goldmann-correlated IOP (IOPg) and corneal-compensated IOP (IOPcc).[@R6] Hence, suggesting that these factors are related to corneal biomechanical properties. In another UK Biobank study, 67 321 participants underwent optical coherence tomography (OCT) imaging of both eyes.[@R7] The OCT is a non-invasive imaging system that provides high-resolution, cross-sectional images of the retina, retinal nerve fibre layer (RNFL) and the optic nerve, aiding in the diagnosis and management of eye diseases.[@R8] Loss of vision due to eye diseases has a considerable impact on an individual's activities and quality of life.[@R9] Identifying modifiable risk factors of common disabling diseases of later life may help develop preventive strategies. These conditions are often caused by a combination of genetics, environmental and lifestyle factors. Built on a foundation laid by the Human Genome Project,[@R11] the last decade has seen dramatic advances in the understanding of molecular mechanisms in the human health and disease. A myriad of studies using traditional linkage methods and genome-wide association studies[@R12] have now raised questions about the role of gene--gene (GxG) and gene--environment (GxE) interaction in determining disease susceptibility.[@R15] Extensive information on environment and lifestyle in conjunction with biological samples are crucial to assess GxE interactions.

To avoid the potential for reverse causality and minimise recall bias, exposures should be measured before they are affected by disease or its treatment. Prospective cohorts offer many advantages for assessing the combined effects of genes, environment and lifestyle factors and its association with various health outcomes. The prospective nature of these cohorts allows the exposures to be recorded before the disease onset, and a wide range of diseases to be investigated, including those that may be challenging to study retrospectively.[@R17] Furthermore, the overall beneficial and adverse effects of a specific exposure on the lifetime risks of numerous diseases can be examined. Only a small proportion of individuals will develop the disease and the effects of various exposures on disease development are likely to be modest. Hence, to address questions of GxG and GxE interaction, prospective studies need to include a large number of participants, with several hundred thousand participants.[@R18] However, there is a lack of large prospective studies at such a scale that allow investigation of risk factors or gene--environmental interaction of eye diseases.

UK Biobank (<https://www.ukbiobank.ac.uk/>) is a large-scale multisite cohort study, conceived to provide a resource for the scientific community to examine genetic and environmental risk factors for complex diseases of middle and old age in the UK population. UK Biobank has collected extensive baseline questionnaire data, physical measures and biological samples, with comprehensive follow-up and characterisation of many different health outcomes.[@R20] Towards the end of the baseline phase, the UK Biobank Steering Committee advised the broadening of the scope of the study to include more detailed examination of participants, including assessment of arterial stiffness, a hearing test, additional cognitive function tests, cardiorespiratory fitness, collection of whole blood and saliva, as well as an examination of eyes and vision. The UK Biobank eye and vision data provide researchers with a unique opportunity to access a very large dataset containing detailed ocular phenotypic information, together with rich biomarker variables, dense genotyping and extensive information on lifestyle variables, medical history and healthcare episodes, thus giving unique research resource. As such, UK Biobank offers comprehensive data to explore novel aetiological associations, risk factors and to make evidence-based recommendations on policy. This report aims to describe the methods and the baseline characteristics of the participants who underwent eye and vision assessment in UK Biobank.

Cohort description {#s2}
==================

Whole UK Biobank cohort {#s2a}
-----------------------

UK Biobank is a large, multisite, study of 502 656 UK residents aged between 40 and 69 years who were registered with the National Health Service (NHS). The overall study protocol (<http://www.ukbiobank.ac.uk/resources/>) and protocols for individual tests (<http://biobank.ctsu.ox.ac.uk/crystal/catalogs.cgi>) are available online. Briefly, extensive baseline questionnaires and physical measures were obtained from 22 assessment centres between January 2006 and October 2010.[@R20] This included data on sociodemographics, family history and early life exposures, psychosocial, environmental, lifestyle, environmental and health status, hearing threshold and cognitive function as well as self-reported medical conditions. In addition to the baseline questionnaire, web-based questionnaires were included to obtain data on dietary intake, occupational history, cognitive function, mental health and gastrointestinal symptoms. In addition, mailed triaxial accelerometers will supplement the physical activity data in 100 000 participants.[@R20]

Physical examination included blood pressure, heart rate, hand grip strength, anthropometrics, spirometry, bone density, arterial stiffness, fitness test. Biological samples, including stored blood, urine and saliva samples, were collected to allow many different types of assay (eg, genetic, proteomic, metabolomics, biochemical and haematologic), (<https://www.ukbiobank.ac.uk/>)[@R22] providing a uniquely rich resource for investigating aetiological risk factors and thereby assisting in the prevention and treatment of many different conditions. The UK Biobank Axiom array was used for genotyping and the methods have been described in detail.[@R23] Furthermore, UK Biobank launched the world's largest health imaging study in 2014 ([www.imaging.ukbiobank.ac.uk](http://www.imaging.ukbiobank.ac.uk)) that aims to perform MRI of brain, heart and abdomen, carotid ultrasound and dual-energy X-ray absorptiometry body scans on 100 000 participants.[@R24] A detailed follow-up of participants over a 20-year period is envisaged through data linkage to national electronic medical records. Thus, linking to NHS will provide valuable information on health outcomes (eg, mortality, cancer registrations, hospital admissions, primary care data, etc).

The key ethics and governance principles relating to UK Biobank are laid out in the Ethics and Governance Framework,[@R22] prepared by the project funders. Major funders include Medical Research Council (MRC) and Wellcome Trust, while other funding bodies include Department of Health (DoH), Scottish Government and the Welsh Government, North West Development Agency, British Heart Foundation and Diabetes UK. All participants provided informed consent.

UK Biobank eye and vision subcohort {#s2b}
-----------------------------------

### Study location {#s2b1}

Ocular measurements commenced in late 2009 at six assessment centres as an additional enhancement to the initial baseline measures. The six centres are distributed across the UK, including Croydon and Hounslow in Greater London, Liverpool and Sheffield in Northern England, Birmingham in the Midlands and Swansea in Wales.[@R6]

### Examination procedures {#s2b2}

#### Questionnaires {#s2b2a}

Self-reported eye diseases, including glaucoma, DR and AMD, were obtained from self-administered questionnaires.

#### Measurements {#s2b2b}

The methods and protocol for the ocular examination component were designed by ophthalmologists from Moorfields Eye Hospital (MEH), London, UK. The core funding for the examination was provided by the Wellcome Trust, the MRC and the DoH. Additional support for training, implementation and quality control came from the NIHR Biomedical Research Centre at MEH. All ocular examinations were undertaken by trained personnel to ensure that the ocular measurements were acquired in a stepwise manner using standard operating procedures or instructions, and they had to pass a structured examination before the project started. The entire process including the teaching material was reviewed and moderated by an ophthalmologist from MEH, London, UK. The ocular examinations were conducted without pharmacological mydriasis and took an average time of 11 min to complete.[@R7] Baseline eye examination was conducted from June 2009 to July 2010, subsequently, from August 2012 to June 2013, a subset of approximately 20 000 underwent follow-up examination, including all eye measures.

#### Visual acuity {#s2b2c}

Visual acuity (VA) was measured using a logarithm of the minimum angle of resolution (LogMAR) chart (Precision Vision, LaSalle, Illinois, USA) on a computer screen under standard illumination. It follows the British Standards Institute,[@R25] and the right eye was measured first. The test was performed with participants wearing the distance refraction at 4 m, or at 1 m if a participant was unable to read. Participants were asked to read each letter from the top of the chart and down as far as possible. The test was terminated when ≥2 letters are incorrect and recorded as LogMAR VA.

#### Refraction {#s2b2d}

Non-cycloplegic autorefraction was performed using the Tomey RC-5000 Auto Refkeratometer (Tomey, Nagoya, Japan) and the right eye was measured first. For each eye, up to 10 measurements were taken and each measurement had a score between 0 and 9 (smaller scores indicate more reliable measurements). To ensure measurements were reliable, each reading achieved a score of ≤4.[@R26]

#### Intraocular pressure {#s2b2e}

IOP was measured using the Ocular Response Analyzer (ORA) (Reichert, Philadelphia, Pennsylvania, USA).[@R27] One measurement was taken for each eye and the right eye was measured first. The ORA uses a rapid pulse air to indent the cornea and an electro-optical system records the corneal deformation. Two applanation measurements are recorded: (1) while the cornea moves inwards, achieving a first applanation state or flattening (P~1~); (2) when the cornea recovers from its slight concave state as the pressure decreases, and the cornea passes through a second applanated state (P~2~). Hence, P~1~ and P~2~ are air pressures that correspond with the two applanation states of the cornea.[@R28] The average of the 2 ORA pressure values was calibrated against Goldmann applanation tonometer to derive IOPg (mm Hg) A separate IOPcc reading (IOPcc=P~1~ and 0.43\*P~2~) was derived to limit the difference before and after laser-assisted in situ keratomileusis (LASIK) surgery and has, therefore, limited influence from corneal biomechanics than those provided by Goldmann applanation tonometer.[@R27]

#### Corneal hysteresis {#s2b2f}

Corneal hysteresis (CH) is considered an indicator of corneal viscous energy damping and is derived as the difference between P~1~ and P~2~: CH=P~1~ and P~2~.[@R27]

#### Optical coherence tomography {#s2b2g}

OCT images were obtained using a spectral domain OCT 3-dimensional (3D OCT-1000 Mark II, Topcon, Japan). The scans were conducted in a darkened room under standard illumination without pupil dilation using a 3D macular volume scan (512 horizontal A-scans/B-scan; 128 B-scans in a 6×6 mm raster pattern). The methodology of the OCT imaging has been described previously.[@R7]

#### Fundus photography {#s2b2h}

Colour photographs of the optic disc and macular were acquired using a Topcon 3D OCT-1000 Mark II system. The Topcon 3D OCT-1000 has a field angle of 45°, a digital zoom (2X, 4X), scanning range of 6×6 mm, 4.5×4.5 mm, 3×3 mm and a scanning speed of 18 000 A-scans per second. The horizontal and longitudinal (depth) resolutions were ≤20 µm and 5--6 µm, respectively.[@R31]

Data monitoring and quality assessment feedback {#s2c}
-----------------------------------------------

Daily monitoring of data collection was performed by UK Biobank using a custom-designed monitoring software (WACMAN). The WACMAN software monitored the data items collected and allowed individual operator's performance to be reviewed---the number of measurements skipped and the degree to which the data collected by the operator lay within the range of expected values. The performance of the technicians responsible for ophthalmic imaging was monitored to provide feedback to those producing substandard quality images within three working days. This was achieved by grading the first 100 photographs of each technician and at least 5% of all OCT images.

Patient and public involvement {#s2d}
------------------------------

UK Biobank maintains a website to keep participants and researchers up to date on the study, which contains a news feed (<http://www.ukbiobank.ac.uk/news/>) and feedback service. In addition, UK Biobank has a twitter feed.

There is an annual scientific meeting which is recorded and available to the public as webcast.

The study was set up by the MRC, DoH and Wellcome Trust with input from major patient representative organisations (British Heart Foundation and Cancer Research UK) <http://www.ukbiobank.ac.uk/public-consultation/>

Statistical analysis {#s2e}
--------------------

The baseline ocular characteristics were analysed and presented as mean±SD for continuous variables and number (%) for categorical variables. Statistical analyses were performed using STATA software V.13.0 (StataCorp).

Results {#s3}
=======

Findings to date {#s3a}
----------------

In total, ocular measures including VA, refraction and IOP data were measured in approximately 117 175 people aged 40--69 years. Of these, OCT imaging and fundus photography were performed in 67 321 (57.5%) participants. [Figure 1](#F1){ref-type="fig"} describes the number of participants with eye measures at baseline and first repeat visit. [Table 1](#T1){ref-type="table"} describes the baseline characteristics of participants in the total cohort, and among participants with various ocular measurements at baseline and at first repeat visits. Compared with the whole UK Biobank cohort, participants with baseline VA and OCT measures consisted of a higher proportion of Asians, blacks and mixed/others ethnic groups and had more positive Townsend Deprivation Index. Compared with participants with baseline eye measures, those with repeat visit of VA or OCT data were older, more likely male, of white ethnic background, had the educational level of degree and above, had more negative Townsend Deprivation Index or better socioeconomic status and less likely to smoke.

![Flow chart of participants with the eye measures at baseline and first repeat visit in the UK Biobank. IOP, intraocular pressure; OCT, optical coherence tomography; VA, visual acuity.](bmjopen-2018-025077f01){#F1}

###### 

Comparison of baseline characteristics between participants in the whole UK Biobank cohort and those with various ocular measurements

                               Total cohort (n=502 665)   Baseline visit of participants with VA data (n=117 175)   First repeat visit of participants with VA data (n=20 202)   Baseline visit of participants with OCT and fundus photography data (n=67 321)   First repeat visit of participants with OCT and fundus photography data (n=17 876)                                                     
  ---------------------------- -------------------------- --------------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ --------------- -------- --------------- -------- ---------------
  Age at recruitment (years)   502 643                    56.5±8.1                                                  117 175                                                      56.8±8.1                                                                         20 201                                                                               57.1±7.4        67 321   56.8±8.2        17 876   57.1±7.4
  Gender                       502 650                                                                              117 175                                                                                                                                       20 201                                                                                               67 292                   17 876   
   Male                                                   229 182 (45.6)                                                                                                         53 413 (45.6)                                                                                                                                                         9866 (48.8)              30 688 (45.6)            8774 (49.1)
   Females ((n)%)                                         273 468 (54.4)                                                                                                         63 762 (54.4)                                                                                                                                                         10 335 (51.2)            36 604 (54.4)            9102 (50.9)
  Ethnicity ((n)%)             499 864                                                                              1 16 290                                                                                                                                      20 151                                                                                               66 809                   17 835   
   White                                                  472 825 (94.6)                                                                                                         104 227 (89.6)                                                                                                                                                        19 713 (97.8)            60 519 (90.6)            17 440 (97.8)
   Chinese                                                1574 (0.3)                                                                                                             535 (0.4)                                                                                                                                                             43 (0.2)                 309 (0.5)                40 (0.2)
   Asian                                                  9882 (2.0)                                                                                                             4504 (3.9)                                                                                                                                                            137 (0.7)                2178 (3.3)               126 (0.7)
   Black                                                  8065 (1.6)                                                                                                             4154 (3.6)                                                                                                                                                            89 (0.4)                 2158 (3.2)               77 (0.4)
   Mixed/other                                            7518 (1.5)                                                                                                             2870 (2.5)                                                                                                                                                            169 (0.9)                1645 (2.4)               152 (0.9)
  Education level ((n)%)       407 211                                                                              98 099                                                                                                                                        17 911                                                                                               56 897                   15 879   
  Less than 'O' level                                     26 892 (6.6)                                                                                                           6410 (6.5)                                                                                                                                                            692 (3.9)                3708 (6.5)               614 (3.9)
   'O' level                                              105 223 (25.8)                                                                                                         24 300 (24.8)                                                                                                                                                         3900 (21.8)              13 990 (24.6)            3437 (21.6)
   'A' level                                              113 879 (28.0)                                                                                                         26 826 (27.4)                                                                                                                                                         4700 (26.2)              15 532 (27.3)            4157 (26.2)
   Degree and above                                       161 217 (39.6)                                                                                                         40 563 (41.3)                                                                                                                                                         8619 (48.1)              23 667 (41.6)            7671 (48.3)
  Townsend Deprivation Index   501 990                    −1.3±3.1                                                  117 035                                                      −0.9±3.0                                                                         20 190                                                                               −2.0±2.7        67 211   −1.0±3.0        17 865   −2.0±2.7
  BMI (kg/m^2^)                499 588                    27.4±4.8                                                  116 510                                                      27.4±4.8                                                                         20 156                                                                               26.9±4.5        66 941   27.4±4.8        17 835   26.9±4.5
  Smoking status ((n)%)        501 724                                                                              116 371                                                                                                                                       20 154                                                                                               66 879                   17 831   
   Never                                                  273 588 (54.5)                                                                                                         64 576 (55.5)                                                                                                                                                         11 897 (59.0)            37 170 (55.6)            10 489 (58.8)
   Former                                                 173 091 (34.5)                                                                                                         40 047 (34.4)                                                                                                                                                         6988 (34.7)              23 206 (34.7)            6211 (34.8)
   Current                                                52 985 (11.0)                                                                                                          11 748 (10.1)                                                                                                                                                         1269 (6.3)               6503 (9.7)               1131 (6.4)

BMI, body mass index; OCT, optical coherence tomography; VA, visual acuity.

[Table 2](#T2){ref-type="table"} summarises the number of participants completing each test and the summary measures for these tests. The VA and refractive error measures were quite similar at baseline and at the first repeat visits. Mean VA was approximately 0.0 LogMAR at both visits. At both visit, the mean spherical equivalent refraction was −0.3 D. Approximately 60% of participants were non-myopic, while the proportion of participants with low, moderate and high myopia were 24%, 11% and 5%, respectively. Participants' mean IOP was slightly higher at first repeat visit than at baseline. The mean IOPg ranged from 15.7 mm Hg to 16.2 mm Hg, while IOPcc ranged from 16.0 mm Hg to 16.5 mm Hg. The proportion of participants with ocular hypertension was 12% at baseline and 16% at first repeat visit. Projected number of new cases of eye diseases including AMD, cataract and primary open angle glaucoma (POAG) expected to occur among the whole UK Biobank cohort and subcohort during the period of 25 years follow-up ([table 3](#T3){ref-type="table"}).[@R32] By 2023, the expected number of new cases of any AMD, cataract and POAG were around 11 753, 107 702 and 8704 in the whole cohort, respectively, with around 14% of these cases occurring in the ocular subcohort. From 2023 to 2033, the expected number of new cases of any AMD increased by 3.5 times, while the expected number of cataract and POAG increased by two times.

###### 

Ocular characteristics of participants in the UK Biobank at baseline visit and at the first repeat visit

  Type of eye test                                   Summary measure                          Baseline visit   First repeat visit                
  -------------------------------------------------- ---------------------------------------- ---------------- -------------------- ------------ ------------
  Visual acuity                                      Mean±SD LogMAR in RE                     116 068          0.03±0.21            20 162       0.00±0.21
  Mean±SD LogMAR in LE                               116 071                                  0.02±0.21        20 153               0.00±0.22    
  Refraction                                         Mean±SD spherical equivalent in RE (D)   114 269          −0.36±2.74           19 505       −0.34±2.86
  Mean±SD spherical equivalent in LE (D)             113 895                                  −0.30±2.76       19 381               −0.31±2.90   
  No of non-myopes (≤−0.50 D)                        69 871                                   60.8             11 636               59           
  No (%) of low myopes (≤−2.99 D)\*                  27 048                                   23.5             4656                 23.6         
  No (%) of moderate myopes (≤−3.00 to ≥−5.99 D)\*   12 033                                   10.5             2336                 11.8         
  No (%) of high myopes (≤−6.00 D)\*                 5917                                     5.2              1095                 5.6          
  Ocular Response Analyzer                           Mean±SD IOPg in RE (mm Hg)               112 292          15.88±3.97           19 515       16.19±4.28
  Mean±SD IOPg in LE (mm Hg)                         111 961                                  15.74±4.02       19 460               16.05±4.30   
  Mean±SD IOPcc in RE (mm Hg)                        112 292                                  16.08±4.35       19 515               16.52±5.05   
  Mean±SD IOPcc in LE (mm Hg)                        111 962                                  16.01±4.40       19 460               16.00±4.84   
  No (%) of ocular hypertension (IOPg \>21 mm Hg)†   14 192                                   12.5             3182                 16.2         

\*Myopia severity defined from either eye.

†Ocular hypertension defined from either eye.

IOPcc, corneal-compensated intraocular pressure; IOPg, Goldmann-correlated intraocular pressure; LE, left eye; LogMAR, logarithm of the minimum angle of resolution; RE, right eye.

###### 

Predicted number of new cases of eye diseases expected to occur during the first 25 years of follow-up in UK Biobank

  Type of eye disease   2018     2023      2028      2033
  --------------------- -------- --------- --------- ---------
  Whole cohort                                       
  AMD                                                
   Any AMD              5455     11 753    22 727    41 205
   NV AMD               3989     8584      16 577    30 007
   GA AMD               3107     6718      13 030    23 663
   Cataract             61 483   107 702   157 499   204 220
   POAG                 5103     8704      13 113    18 296
  Ocular subcohort\*                                 
  AMD                                                
   Any AMD              766      1649      3186      5761
   NV AMD               560      1204      2322      4198
   GA AMD               437      944       1829      3317
   Cataract             8593     14 984    21 787    28 093
   POAG                 708      1207      1817      2532

Adapted from Desai *et al*.[@R32]

\*Ocular subcohort who had ophthalmic assessment at baseline, including retinal imaging.

AMD, age-related macular degeneration; GA, geographic atrophy; NV, neovascular; POAG, primary open angle glaucoma.

Findings from the UK Biobank eye data showed that first-born individuals were more often myopic than non-first-born,[@R33] which confirms previous findings.[@R34] New findings include the discovery of 112 loci, including 68 novel loci, associated with IOP and the development of POAG. Several loci suggest the importance of angiopoietin-receptor tyrosine kinase (ANG-TEK) in signalling IOP regulation, thus suggesting ANG-TEK to be a therapeutic target. In individuals without neurodegeneration, thinner RNFL was associated with worse cognitive function and more likely to have future cognitive decline.[@R36] The use of deep-learning models predicted cardiovascular risk factors such as age (mean absolute error within 3.26 years), gender (area under the curve (AUC)=0.97), smoking status (AUC=0.71), systolic blood pressure (mean absolute error within 11.23 mm Hg) and major adverse cardiac events (AUC=0.70).[@R37]

Discussion {#s4}
==========

Common age-related eye diseases, including AMD, DR, glaucoma and myopia, are leading causes of visual impairment,[@R38] and have both genetic and environmental contributions. Smoking and age are the most consistently observed non-genetic risk factors for AMD,[@R39] and several established genetic risk factors have been identified.[@R40] Significant gene--environmental interactions have been identified for complement factor H gene and smoking for AMD.[@R42] However, limitations exist and generalisability of the findings is uncertain. Hence, future prospective studies of larger sample size would help to clarify the issue. The UK is in an ideal position to undertake ambitious 'big data' health sciences research, given the extensive coverage of the NHS and various detailed health record systems. UK Biobank has begun to harness these strengths to deliver epidemiological research at scale. Repeating detailed physical measures every few years in subsets of 20--25 000 participants adds a powerful longitudinal dimension, with health-related outcomes being tracked through linkage to NHS records including death and cancer registers, hospital inpatient and outpatient episodes and primary care. Other health record linkage including data from national mental healthcare, residential history, laboratory and disease audit datasets, National Ophthalmology Database Audit, OpenEyes, Medisoft Ophthalmology, and may also include imaging, cancer screening and dental.[@R20] To enhance accurate identification of health outcomes, additional methods such as cross-referencing against NHS case records, imaging and eye data or banked tissues will be used for validation and subclassification.

Scope of eye data {#s5}
=================

UK Biobank is among the largest eye and vision datasets globally. By 2023, \>11 000 incident cases of AMD, \>8000 cases of POAG and about 107 000 cataract surgeries will have occurred in the whole UK Biobank cohort.[@R32] This large number of new cases of eye diseases will provide substantial power for nested case--control studies to detect the main effect OR of 1.3 or higher.[@R43] With the rise in ageing population, the rates of chronic eye diseases will increase. However, the rates of undiagnosed eye diseases remain high. Population-based studies reported that at least 50% of whites,[@R44] and 55%--90% of Asians[@R48] have undiagnosed glaucoma. Approximately 70% of undiagnosed cataracts were reported in USA[@R51] and Singapore.[@R52] In addition to undiagnosed eye conditions, people were found to be unaware of their eye conditions. Previous population-based reported that only 5%--46% of those identified as having an eye disease (eg, AMD,[@R53] cataract,[@R53] glaucoma and DR,[@R54] accurately self-reporting their disease).[@R55] Hence, linking to electronic health records is essential to ensure accuracy in identification of eye diseases. In UK Biobank, the overall self-reported glaucoma rate was 1.7% among people aged 40--69 years.[@R56] This rate appears to be lower compared with White populations aged 40 years and older in the USA (2.08%),[@R46] Australia (2.0%)[@R57] and Italy (2.9%).[@R58]

Retina and the cardiovascular system {#s6}
====================================

Retinal imaging has provided probably the richest data relating to eyes and vision in UK Biobank. In addition to giving unprecedented power to examine diseases of the eye, retinal morphometry can give insights into the diseases of the vascular and neurological systems. The retina shares similar embryological origin, anatomical features and physiological properties with the brain,[@R59] it offers an accessible site to investigate the central nervous system in vivo.[@R60] Using fundus photographs, retinal microvascular morphometry offers the prospect of meaningful improvements in risk stratification in cardiovascular disease.[@R61] [Table 4](#T4){ref-type="table"} summarises major longitudinal cohort studies (n\<10 000) on an eye and systemic diseases that were performed among the Western populations[@R62] and Asian populations.[@R69] Early signs of elevated risk of major systemic diseases, such as diabetes mellitus,[@R76] stroke,[@R77] hypertension[@R80] and cardiovascular diseases,[@R81] can be detected in the retinal blood vessels. The advent of powerful computer-based algorithms offers the prospect of truly ground-breaking advances in medical care.[@R37] A recent study demonstrated that the application of deep learning to retinal fundus images can be used to predict cardiovascular risk factors such as age, gender and smoking status.[@R37]

###### 

Characteristics of prospective cohort studies on eye diseases (n≤10 000)

  Study (location)                                                                 Location                     Age range (years)   Ethnicity              Date of baseline eye examination (N)                             Date of follow-up eye examination (N)                                       Type of ocular measures                                                                                                                                                                                                                                                                Major eye conditions examined
  -------------------------------------------------------------------------------- ---------------------------- ------------------- ---------------------- ---------------------------------------------------------------- --------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Western population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
   Wisconsin Epidemiologic Study of Diabetic Retinopathy (Southern Wisconsin)      Southern Wisconsin, USA      \<30                Whites                 1980--1982 (n=996 (type 1 diabetes), n=1370 (type 2 diabetes))   1984--1986, 1990--1992, 1994--1996, 2000--2001, 2005--2007                  Fundus photography.                                                                                                                                                                                                                                                                    Diabetic retinopathy.
   Beaver Dam Eye Study (Beaver Dam, Wisconsin)                                    Beaver Dam, Wisconsin, USA   43--84              Predominantly whites   1988--1990 (n=4926)                                              5 years (n=3722), 10 years (n=2962), 15 years (n=2375), 20 years (n=1913)   Visual acuity, non-cycloplegic autorefraction, fundus photography, photograph of the crystalline lens.                                                                                                                                                                                 Refractive error, diabetic retinopathy, macular degeneration, cataract.
   European Prospective Investigation of Cancer-Norfolk Eye Study (East England)   East England                 48--92              Predominantly whites   2004--2011 (n=8623)                                              NA                                                                          Visual acuity, non-cycloplegic autorefraction, biometry, tonometry, Ocular Response Analyzer, corneal biomechanical measures, scanning laser polarimetry, confocal scanning laser ophthalmoscopy, fundus photography and automated perimetry.                                          Refractive error, glaucoma, age-related macular degeneration and visual impairment.
   Blue Mountains Eye Study (Sydney, Australia)                                    Sydney, Australia            ≥49                 Predominantly whites   1992--1994 (n=3654)                                              1997--1999 (n=2335), 2002--2004 (n=1952)                                    non-cycloplegic autorefraction, fundus photography, Retroillumination lens photograph, slit-lamp lens photograph.                                                                                                                                                                      Cataract, macular degeneration, glaucoma, myopia, diabetic retinopathy.
   Los Angeles Latino Eye Study (Los Angeles, USA)                                 Los Angeles, USA             ≥40                 Latinos                2000--2003 (n=6357)                                              2004--2008 (n=4658)                                                         Visual acuity, non-cycloplegic autorefraction, tonometer, ultrasonic A-scan/pachymeter, slit-lamp examination of anterior and posterior segments, fundus photography, automated perimetry.                                                                                             Cataract, macular degeneration, glaucoma, diabetic retinopathy, visual impairment and blindness.
  Asian population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
   Beijing Eye Study (Beijing, China)                                              Beijing, China               ≥40                 Chinese                2001 (n=4439)                                                    2006 (n=3251), 2011 (n=2695)                                                Visual acuity, non-cycloplegic autorefraction, slit-lamp examination of the anterior segment, lens and corneal photography, fundus photography, tonometry, visual field test.                                                                                                          Refractive error, cataract, age-related macular degeneration, glaucoma, diabetic retinopathy, retinal vein occlusions, visual impairment and blindness.
   Singapore Malay Eye Study (Singapore)                                           Singapore                    40--80              Malay                  2004--2006 (n=3280)                                              2011 (n=1900)                                                               Visual acuity, subjective refraction, ocular biometry, slit-lamp and dilated eye examination, Goldmann tonometry, lens photography, fundus photography, retinal tomography, retinal optical coherence tomography, fundus autofluorescence imaging, gonioscopy and visual field test.   Refractive error, cataract, age-related macular degeneration, glaucoma, diabetic retinopathy, visual impairment and blindness.
   Handan Eye Study (Handan, China)                                                Handan, China                ≥30                 Chinese                2006--2007 (n=6830)                                              NA                                                                          Visual acuity, subjective refraction, ocular biometry, fundus photography, optical coherence tomography, tonometry, visual field test.                                                                                                                                                 Refractive error, age-related macular degeneration, glaucoma, diabetic retinopathy.
   Aravind Comprehensive Eye Study (Tamil Nadu, South India)                       Tamil Nadu, south India      ≥40                 Indians                1995--1997 (n=5150)                                              NA                                                                          Visual acuity, subjective refraction from retinoscopy, slit-lamp examination of the anterior and posterior segments, gonioscopy, fundus photography, Goldmann tonometry, visual field test.                                                                                            Glaucoma, age-related macular degeneration, visual impairment.

NA, not applicable.

Neurodegenerative diseases including Parkinson's disease (PD), Alzheimer's disease (AD) and multiple sclerosis (MS) all have a measurable effect on the retina. Recent studies using OCT showed differences in inner retinal layers between the normal population and participants with PD,[@R82] AD[@R83] and MS.[@R84] Studies have shown reduction in the ganglion cell layer along with the inner plexiform layer in patients with AD compared with healthy controls,[@R85] while others reported thinning in the RNFL, especially in the superior and inferior quadrants.[@R83] With a large cohort and detailed measurements at multiple time points, the UK Biobank is able to assess if changes in the eye precede development of these conditions or are a consequence from the neurodegenerative conditions.

Comparison with other cohorts, biobanks and consortia {#s6a}
-----------------------------------------------------

[Table 5](#T5){ref-type="table"} describes large prospective cohorts (\>10 000) that examine associations with eye diseases. European studies include the Rotterdam Study of 14 926 participants aged 45 years or older[@R91] and the Gutenberg Health Study of 14 700 participants aged 35--74 years.[@R92] In Asia, the Kangbuk Samsung Health Study performed health screening on 281 238 employees aged 20 years and older. However, there are limited ocular measurements with the KSH study.[@R93] Large prospective studies are well suited for investigating the risk factors for diseases and could either be conducted as a biobank such as the UK Biobank,[@R22] China Kadoorie Biobank[@R95] and The American Cancer Society's Cancer Prevention Study 3[@R96] or a consortium such as the P~3~G consortium,[@R97] National Cancer Institute Cohort Consortium,[@R98] Cohorts for Heart and Aging Research in Genomic Epidemiology[@R99] and European Eye Epidemiology (E3) consortium. However, eye measures are not available on most of these large prospective studies except the UK Biobank and E3 consortium. The major differences between the biobank design and consortia are that the latter are often developed by pooling data from different studies with disparate consent/governance procedures that may limit the power to address previously unanticipated research questions.[@R100] Moreover, there is more variability in sampling, measurements of exposures and identification of diseases ascertained.[@R101] In contrast, biobanks are usually planned in advance with uniformity in collection of samples and genotyping has been carried out according to a predetermined strategy. Thus, consortia are typically regarded as less robust because of problems with direct and imputed genotyping, and non-standardised diagnostic criteria.

###### 

Characteristics of prospective cohort studies on eye diseases (n≥10 000)

  Study (location)                                                Age range (years)                                                        Ethnicity   Date of baseline eye examination (N)    Date of follow-up eye examination (N)                                                                              Type of ocular measures                                                                                                                                                                                                                                Major eye conditions examined
  --------------------------------------------------------------- ------------------------------------------------------------------------ ----------- --------------------------------------- ------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------
  Western population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
   Rotterdam study (Rotterdam, Netherlands)                       ≥45                                                                      White       Study 1-baseline: 1990--1993 (n=7983)   Study 1: 1993--1995 (n=6315), 1997--1999 (n=4797), 2002--2004 (n=3550), 2009--2011 (n=2147), 2014--2015 (n=1153)   Visual acuity, subjective refraction, corneal topography, keratometry, ocular biometry, slit-lamp examination of the anterior segment, tonometry, optical coherence tomography, fundus photography, fundus autofluorescence and automated perimetry.   Myopia, macular degeneration, glaucoma.
  Study 2-baseline: 2000--2001 (n=3011)                           Study 2: 2004--2005 (n=2468), 2011--2012 (n=1893), 2015--2016 (n=1408)                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Study 3-baseline: 2006--2008 (n=3932)                           Study 3: 2012--2014 (n=3122).                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
   Gutenberg Health Study and Ophthalmic Study (Mainz, Germany)   35--74                                                                   White       2007--2012 (n=15 010)                   2012--2017 (n=14 700)                                                                                              Visual acuity, non-cycloplegic autorefraction, tonometer, pachymetry/keratometry, slit-lamp of the anterior segment, fundus photography, automated perimetry.                                                                                          Macular degeneration, glaucoma, diabetic retinopathy.
  Asian population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
   Kangbuk Samsung Health Study (Seoul and Suwon, South Korea)    ≥20                                                                      Korean      2002 (n=281 238)                        Every 1--2 years                                                                                                   Tonometer, fundus photography.                                                                                                                                                                                                                         Glaucoma.

Strengths and limitations {#s6b}
-------------------------

UK Biobank is the only prospective study with a very large sample size (\>100 000) of participants with a range of eye measures. With the projected number of new cases diagnosed with a range of eye diseases, it will allow researchers to investigate the genetic, environmental and lifestyle risk factors of various eye diseases. In addition, there are intensive methods to ascertain outcomes with electronic and semiautomated sources for validation and sub classification.[@R20]

Despite the scope of eye data collected in the UK Biobank, limitations exist within the study. One important limitation of UK Biobank was its low response rate (5.5%), and that participants were more likely to be from a healthier, more affluent sector of the UK population. However, it is unlikely that the direction of the association is opposite in respondents and non-respondents, and hence representativeness is not a major concern. The UK Biobank was not set up to be representative of the general UK population. More importantly, the large sample size and extensive exposures allow for valid scientific inferences of associations between exposures and health outcomes that are generalisable to the wider population. In addition, a large number of cases allow the detection and quantification of small effect sizes. Eye measurements were performed in 6 out of 22 of the assessment centres and participants with eye measures tend to have an education level of degree and above compared with the whole UK Biobank cohort. Hence, they may come from a more affluent sector and may not represent the whole UK Biobank cohort. The first repeat eye measure was only performed in approximately 20 000 participants. However, a repeat of the baseline visit will be conducted every few years in subsets of 20--25 000 participants. The self-reported nature of eye diseases may result in recall bias and misclassification error. However, the biases should be minimal as the ascertainment of outcomes will be conducted through linkages to national healthcare database, relevant administrative databases and analysis of available phenotypic data. We have access to medical records.[@R32]

Collaboration {#s7}
=============

UK Biobank aims to provide open access data for health-related research and the data are made available to all bona fide researchers from the academic, charity, public and commercial sectors, both in the UK and internationally, without preferential or exclusive access for any user.[@R20] All interested researchers may apply to access the data via an online application. Strict guidelines are in place to help ensure anonymity and confidentiality of participants' data and samples.[@R103]

Conclusion {#s8}
==========

UK Biobank Eye and Vision data would allow investigation of the factors leading to the onset and disease progression of major eye diseases. In addition, the ocular phenotypes could be explored with systemic diseases such as diabetes, hypertension and neurological diseases. In conclusion, the extensive exposures and health outcomes available in the UK Biobank will provide scientists with insights into the predictors of ocular and systemic diseases, allowing customised treatment therapies and interventions tailored to the individual patient. Furthermore, its collaborative and multidisciplinary research allows scientists to use known or innovative methods to explore and further develop techniques and treatment strategies that could have a major impact on the field of biomedical, behavioural or clinical research.
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